Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CLL Risk Stratification and Treatment Approach

January 13th 2017

Chronic Lymphocytic Leukemia; Initiating Therapy

January 13th 2017

Emerging Therapies for Follicular Lymphoma

January 13th 2017

R2-CHOP for Relapsed Follicular Lymphoma

January 13th 2017

Sequencing Therapies for Follicular Lymphoma

January 13th 2017

Follicular Lymphoma: Consolidation and Maintenance

January 13th 2017

Follicular Lymphoma; Triggers to Initiate Therapy

January 13th 2017

Emerging Therapies for CML

January 13th 2017

Transplant for Chronic Myeloid Leukemia

January 13th 2017

Treatment of Relapsed/Refractory CML

January 13th 2017

Relapse After CML Treatment Discontinuation

January 13th 2017

The NILSt and D-STOP Trials in CML

January 13th 2017

Treatment-Free Remission in CML

January 13th 2017

Managing Toxicities from BCR-ABL TKIs in CML

January 13th 2017

Monitoring Response to CML Therapy

January 13th 2017

Early Molecular Responses in CML

January 13th 2017

Treatment Choice in CML

January 13th 2017

TIDEL-II Trial for CML

January 13th 2017

Diagnosis and Upfront Therapy for CML

January 13th 2017

Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma

January 12th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.